The Watchman is a small, permanent implant placed inside the heart to prevent strokes in people with atrial fibrillation (AFib). It works by sealing off a tiny pouch in the heart where dangerous blood clots tend to form, offering an alternative to long-term blood thinners. The device is about the size of a quarter, shaped like a parachute, and sits inside the heart for life.
How the Device Works
In people with AFib, the heart’s upper chambers quiver instead of beating in a steady rhythm. This irregular motion allows blood to pool and clot, especially in a small, finger-shaped sac called the left atrial appendage. The vast majority of stroke-causing clots in AFib patients form in this one spot.
The Watchman is a self-expanding device with a woven fabric cap attached to a wire frame. Once placed inside the left atrial appendage, it opens like an umbrella and plugs the opening. Over roughly 45 days, a thin layer of the body’s own tissue grows over the cap, permanently sealing the pouch off from the bloodstream. Clots can still form inside the appendage, but they can no longer escape into circulation and travel to the brain.
Who Qualifies for the Watchman
The device is FDA-approved for people with non-valvular AFib who are at elevated stroke risk and would normally be recommended blood thinners. It’s not a first-line option for everyone with AFib. Instead, it’s designed for patients who have a legitimate reason to avoid long-term anticoagulation therapy.
Common reasons a doctor might recommend the Watchman include a history of serious bleeding while on blood thinners, a job or lifestyle that puts you at high risk for traumatic bleeding, or difficulty tolerating anticoagulation medications. Your doctor will assess your individual stroke risk using a scoring system that factors in age, prior stroke history, high blood pressure, diabetes, heart failure, and vascular disease. The higher your score, the stronger the case for some form of stroke prevention.
The device is not an option if you already have a blood clot inside the heart, if your left atrial appendage is an unusual shape or size that won’t accommodate the implant, or if you’ve previously had certain other heart closure devices implanted. You also need to be able to tolerate blood thinners temporarily after the procedure while tissue grows over the device.
What Happens During the Procedure
The Watchman is implanted through a catheter-based procedure, meaning there’s no open-heart surgery involved. The entire implantation typically takes about an hour, though preparation and recovery add several more hours to your day at the hospital.
Your doctor accesses the heart through a vein in the groin, threading a thin catheter up through the blood vessels and into the heart’s left atrium. The device is pushed through the catheter into the left atrial appendage, where it expands and locks into place. Imaging guidance, including ultrasound from inside the esophagus, helps the doctor position the device precisely. Most patients go home the next day.
Recovery and Medications After Implantation
The goal of the Watchman is to get you off blood thinners, but that doesn’t happen immediately. Your body needs time to grow tissue over the device before it can do its job independently. During this transition, you’ll stay on a temporary medication regimen to prevent clots from forming on the device itself.
The standard protocol originally involved taking a blood thinner plus low-dose aspirin for the first 45 days, then switching to two antiplatelet medications for up to six months, followed by aspirin alone indefinitely. More recently, the FDA approved a simplified option for the newer Watchman FLX model: two antiplatelet medications for just 45 days as an alternative to the blood thinner combination. Your doctor will recommend the approach that fits your bleeding risk and medical history.
At the 45-day mark, you’ll have a follow-up imaging study to confirm the device is properly seated and that tissue has begun growing over it. If everything looks good, your doctor will step down your medications according to the planned timeline.
How It Compares to Blood Thinners
Long-term data comparing the Watchman to warfarin (the traditional blood thinner for AFib) shows meaningful benefits. In a major clinical trial published in JAMA, the device reduced the combined risk of stroke, blood clots traveling to other organs, and cardiovascular death by roughly 50% compared to warfarin. Hemorrhagic stroke, the type caused by bleeding in the brain, occurred in just 0.6% of device patients versus 3.7% of those on warfarin. Major bleeding overall was also lower in the device group: 4.8% compared to 7.4%.
These numbers reflect the core trade-off. Blood thinners reduce clotting but increase bleeding risk everywhere in the body, including the brain and gut. The Watchman addresses the clotting problem mechanically, at its source, without that ongoing bleeding trade-off.
Risks and Complications
Like any heart procedure, Watchman implantation carries some risk, though complication rates are low. Data from a large U.S. registry of nearly 100,000 patients receiving the newer Watchman FLX device provides a clear picture of what can go wrong.
Pericardial effusion, where fluid collects around the heart and needs to be drained, occurred in about 0.5% of patients within 45 days. The vast majority of these cases were treated with a needle drainage procedure rather than surgery. Device embolization, where the implant dislodges and moves out of position, happened in just 0.04% of cases (roughly 4 in 10,000). Blood clots forming on the device itself, known as device-related thrombus, were detected in 0.44% of patients who had follow-up imaging at 45 days.
These numbers have improved significantly from earlier versions of the device, partly due to better designs and partly due to growing physician experience with the procedure.
The Latest Version: Watchman FLX Pro
The newest iteration, the Watchman FLX Pro, received FDA approval in 2023. It includes a polymer coating designed to resist clot formation on the device surface. In preclinical testing, this coating reduced inflammation by 86% in the first three days after implantation, cut clot formation by 70% at two weeks, and increased tissue coverage by 50% at the 45-day mark compared to earlier models. The FLX Pro also comes in a larger size option, allowing doctors to treat patients whose left atrial appendages were previously too big for the device.
Insurance and Medicare Coverage
Medicare covers the Watchman procedure, but with specific requirements. Under the current national coverage policy, you must have a formal shared decision-making conversation with an independent physician who is not the one performing the procedure. This conversation must use an evidence-based decision tool that walks through the risks and benefits of blood thinners versus the device, and it must be documented in your medical record. Private insurers generally follow similar criteria, typically requiring documentation that blood thinners are problematic for you before approving the procedure.